Excelvision - Fareva — FDA Warning Letter, 2026-06-25: CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: The FDA's Center for Drug Evaluation and Research issued a warning letter (320-26-98) to Excelvision - Fareva on June 25, 2026, following an inspection of its Annonay facility (FEI 3007058211) from January 12-22, 2026, citing significant Current Good Manufacturing Practice violations for finished pharmaceuticals. The firm failed to conduct thorough investigations of sterile drug product contamination complaints spanning three years, including nine non-sterility events involving mold, black specks, and discoloration; inadequately assessed environmental and personnel monitoring data linking identified microorganisms (such as Alternaria alternata) to manufacturing areas; and largely attributed contamination to customer mishandling without scientific evidence, rendering drug products adulterated under 21 CFR parts 210-211 and the FD&C Act. The FDA found the firm's proposed corrective actions inadequate, specifically rejecting its explanation for how contamination occurred in products released as sterile and expressing concern about container-closure system suitability.
Argus analysis
# FDA Warning Letter Analysis: Excelvision-Fareva
**Company and Findings**
Excelvision-Fareva, a pharmaceutical manufacturing facility in Annonay, France (FEI 3007058211), received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on June 25, 2026, following an inspection conducted January 12–22, 2026. The FDA determined that the company's finished pharmaceutical drug products are adulterated because manufacturing methods, facilities, and controls fail to meet Current Good Manufacturing Practice (CGMP) standards. The core issue involves repeated contamination events in sterile products, particularly the presence of mold, black specks, and discoloration in containers—nine non-sterility incidents documented over three years.
**Regulatory Citations**
The violations center on 21 CFR 211.192, which requires firms to thoroughly investigate batch failures and discrepancies, determine root causes scientifically, and implement corrective and preventive actions (CAPAs). The broader framework stems from 21 CFR parts 210 and 211, establishing CGMP requirements for finished pharmaceuticals. These citations typically indicate systemic deficiencies in quality oversight: inadequate complaint investigation procedures, failure to correlate environmental monitoring data with contamination events, and insufficient assessment of container-closure system integrity—critical for products designed to maintain sterility during consumer use.
**Response Requirements and Industry Watch Points**
Excelvision-Fareva must provide a comprehensive response addressing investigation system overhaul, retrospective batch reviews, microbial challenge studies, and container-closure system evaluation. The company indicated two aseptic processing lines would cease U.S. production and be replaced. Industry observers should monitor whether the firm submits timely, scientifically rigorous responses and whether the FDA issues a close-out letter confirming compliance. Product recalls, manufacturing suspensions, or import alerts remain possible enforcement actions if remediation proves inadequate.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Excelvision - Fareva MARCS-CMS 726714 — June 25, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Product: Drugs Recipient: Recipient Name Mr. Bernard Fraisse Recipient Title CEO Excelvision - Fareva 1041 Chemin de la Digue du Rhône 07300 Tournon-sur-Rhône France BFraisse@fareva.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-98 June 25, 2026 Dear Mr. Fraisse: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Excelvision, FEI 3007058211, at 27 Rue de la Lombardiere, Annonay, from January 12 to 22, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 12, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). You failed to adequately investigate customer complaints for the various sterile (b)(4) drug products (prescription and over-the-counter) you manufacture. Your investigations were not thorough, did not appropriately expand in scope, and lacked a scientifically supported determination of root causes. You also failed to identify and implement adequate and timely corrective actions and preventive actions (CAPAs). Your product is intended to maintain sterility of its contents after (b)(4) by the consumer. However, since our previous inspection in November 2024, your firm has received a substantial number of complaints related to the presence of contamination. Visible evidence of contamination included mold, black specks, and discoloration on the tips and inner caps of containers for your (b)(4) drug product, (b)(4) . Several complaint samples subsequently failed sterility testing. Notably, nine such non-sterility events have occurred in the last three years. You failed to adequately determine which hazards in your manufacturing operation and container-closure systems led to these critical, repeated incidents of contamination in your (b)(4) drug products. Specifically, you failed to adequately investigate potential container-closure integrity defects that would allow ingress of microb…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Excelvision - Fareva had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Excelvision - Fareva as of 2026-06-30. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Excelvision - Fareva — FDA Warning Letter, 2026-06-25: CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-excelvision-fareva-2026-06-25-cgmp
"Excelvision - Fareva — FDA Warning Letter, 2026-06-25: CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-excelvision-fareva-2026-06-25-cgmp.
Argus HQ Research. "Excelvision - Fareva — FDA Warning Letter, 2026-06-25: CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-excelvision-fareva-2026-06-25-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_excelvision_fareva_2026_06_25_cgmp_2026,
title = {Excelvision - Fareva — FDA Warning Letter, 2026-06-25: CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-excelvision-fareva-2026-06-25-cgmp},
note = {Accessed: July 13, 2026}
}